Ampyra Tablet, Film Coated, Extended Release
Product Images NDC 10144-427

5 FDA label images from Merz Pharmaceuticals, Llc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Ampyra (NDC 10144-427). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Merz Pharmaceuticals, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Crcl-eqn-102716.jpg (Crcl Eqn 102716)

Crcl-eqn-102716.jpg (Crcl Eqn 102716)
Chemical formula image presenting a formula for creatinine clearance (CrCl) involving age, weight in kilograms, serum creatinine (SerumCr) in mg/dL, and constants for calculation.*
FDA Label Image

Chemical Structure (Ampyra 01)

Chemical Structure (Ampyra 01)
Chemical structure of dalfampridine shown as a pyridine ring with an amino group attached. The diagram represents the molecular structure of the active ingredient in AMPYRA 10 mg extended-release tablets by Merz Pharmaceuticals.*
FDA Label Image

Figure 1 (Ampyra 02)

Figure 1 (Ampyra 02)
A bar chart comparing the percentage of patients with various levels of average percent increase in walking speed from baseline between those treated with AMPYRA 10 mg twice daily and placebo. The chart includes statistical p-values comparing AMPYRA to placebo at each threshold, showing significantly higher improvement in walking speed for AMPYRA-treated patients at lower thresholds.*
FDA Label Image

Figure 2 (Ampyra 03)

Figure 2 (Ampyra 03)
A bar chart comparing the percentage of patients achieving various average percent increases in walking speed from baseline, contrasting AMPYRA 10 mg b.i.d. treatment with placebo. The chart includes p-values indicating statistical comparisons at different walking speed increase thresholds.*
FDA Label Image

Patheon (Ampyra Botle Label2024)

Patheon (Ampyra Botle Label2024)
Label for AMPYRA (dalfampridine) Extended Release Tablets, 10 mg strength, oral extended-release film-coated tablets. The bottle contains 60 tablets, labeled for prescription use only. Manufactured by Acorda Therapeutics, LLC, with storage and safety instructions visible on the label alongside the NDC barcode.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.